Maxcyte Share Discussion Threads

[jitters3] 05/10/2021 10:29

I have a account with Halifax share dealing because of AJB I trade MXCT and JSE on there if that helps

[thetrotsky] 05/10/2021 09:50

Can anybody suggest an alternative broker to AJ Bell. The more I think about it the more incensed I am by their action. I have sent them messages this morning to advise that I am now looking to move my accounts elsewhere. How dare they stop trading on the UK market without any warning! Maxcyte have not applied to de-list in the UK (as yet) and as such AJ Bell's move is totally arbitrary and is no way beneficial to me

[assagai] 05/10/2021 09:49

Charles Stanley...

[thetrotsky] 05/10/2021 09:26

I have to say that this is a very bizarre move by AJ Bell and also very detrimental. Personally, I am unhappy to place my (advance) orders over the phone to trade in a window that tends to be to the downside (the US market often trades down to start and then rises towards the end of the session from what I've seen). AJ Bell are throwing us to the wolves and if they are unwilling to provide online trading during from open to close in the US then I will be looking to take my accounts elsewhere.

[lancasterbomber] 04/10/2021 15:48

I was just going to post the same.
I sent them a secure message on Friday because I thought there was an error since the share price was quoted in dollars, even though ADVFN were quoting in dollars.

You have missed off your note the sting in the tail you can only deal by phone and during the hours of 2.30pm and 5pm.


Letter from AJB

Good afternoon,



I’m writing to let you know about a change in dealing arrangements for MaxCyte Inc.



MaxCyte Inc is a US security that is traded on the UK AIM market via a Depositary Interest (DI) and on the US Nasdaq exchange.



To date we have offered online dealing in the UK DI based listing, however there are now substantially greater volumes of shares traded each day on the US Nasdaq exchange.



This increased liquidity means better price outcomes can be obtained by trading directly on the US exchange, even allowing for foreign exchange currency conversion costs.



To ensure we continue to obtain the best prices for our customers in this security we have now moved all trading to the US exchange.



Please note however that currently there is no online or mobile app dealing available for the US exchange listing and any orders you place with us can only be placed by calling us on 0345 54 32 600 between 2.30pm and 5pm.



Phone orders will be charged at our standard online dealing rate, however our foreign exchange charge will apply, please see here for full details.



If you have any questions relating to this change please contact us at [e-mail]

[adamb1978] 04/10/2021 15:42

Interesting. I just received this from AJ Bell:

Good afternoon,



I’m writing to let you know about a change in dealing arrangements for MaxCyte Inc.

MaxCyte Inc is a US security that is traded on the UK AIM market via a Depositary Interest (DI) and on the US Nasdaq exchange.

To date we have offered online dealing in the UK DI based listing, however there are now substantially greater volumes of shares traded each day on the US Nasdaq exchange.

This increased liquidity means better price outcomes can be obtained by trading directly on the US exchange, even allowing for foreign exchange currency conversion costs.

To ensure we continue to obtain the best prices for our customers in this security we have now moved all trading to the US exchange."

[trident5] 02/10/2021 09:52

But he will continue to provide consulting services. Which seems a little un-non-executive, unless he's consulting on the Chair's role - which will hardly endear the position to a new incumbent.

[davep4] 01/10/2021 23:45

The Chairman was 80 this year, so I think he deserves a rest!

[edwardt] 01/10/2021 15:55

Going to raid the piggy bank next week for a few. Been a hell of a ride but this bump in the road has made me greedy for a few more

[adamb1978] 01/10/2021 15:23

Trident

OK. You seem to have a grudge against this company given you regularly post negative comments on here. I'm all for two-sided debates, and discussion over the pros and cons of a company (and one of the weaknesses of advfn is that there are too many boards with people constantly high-fiving and exaggerating a company's potential) however when someone spends so much time posting negatively about a company, it suggests some undisclosed motive as I cant see why anyone sane would waste energy on something which didnt matter to them.

I'm therefore going to put you on filter and leave you to debate with others.
All the best for the future,

Adam

[rgmgo] 01/10/2021 15:21

It never rains, but it pours. hxxps://www.wsj.com/articles/deaths-raise-safety-concerns-around-gene-therapy-11633080601 If you can't access the article you can also try searching by the title: Deaths Raise Safety Concerns Around Gene Therapy. I guess at least we can say that the risk reward is getting interesting again, industry wide concerns are the biggest single threat to MXCT but having raised US capital at a premium to the current price, equity value has taken quite a thump at a time the company has continued to expand its pipeline of potential SPL partner royalties.

[trident5] 01/10/2021 15:04

Adam - yes just out. After reading about it elsewhere - that's not good.

I notice that after standing down his stock options continue to vest.

And my comment about 7 NEDs was sarcastic. This is a very small company and outsiders had to tell them to keep CARMA for the licensing revenue - so I'm not sure what value they add.

[adamb1978] 01/10/2021 15:00

Trident5 - they have, and obviously they'll appoint another Chairman.

And 7 NEDs is fine! 'Just' 7 NEDs??!? Not sure whether that was a sarcastic comment

[adamb1978] 01/10/2021 14:59

The chairman standing down I dont see as a problem - he's in his 70s and the Nasdaq listing should now help them to secure a decent successor.

Lots of growth stocks are getting whacked at the moment. Zoom is down over 50% from its highs. BLI is down over 80%!

Clearly these sort of drops aren't nice but if you're in this for the long-term, then hopefully it should be an irrelevance

[trident5] 01/10/2021 14:52

Why haven't Maxcyte issued an RNS telling us that the Chair is stepping down?

If they don't replace him they'll be down to just 7 NEDs.

[nimbo1] 01/10/2021 14:45

I think there a couple of other things impacting sentiment on top of general market sell off... Berkeley lights short report from a couple of weeks back (nothing to do with maxcyte) but charts look remarkably similar since and negative article in Wall Street journal on gene editing.

[acuere] 01/10/2021 14:43

News that the Chairman is stepping down seems to be the catalyst for todays kicking on the Nasdaq.
Company needs to announce some more SPLs to keep growth story alive. I was disappointed in the H1 results that the potential clinical programs were now over 75. At the previous results there were over 100.

[mysteronz] 01/10/2021 14:30

A few more added just now - £200m in cash don’t forget!

[adamb1978] 29/9/2021 14:57

The price is coming off simply because 10 yr yields are increasing, which hits growth stocks. I'm not sure it is anything more than that

[rgmgo] 29/9/2021 13:48

I think we have to recognise that there are a lot of moving parts with the MXCT story and we are still at an early stage, so volatility will likely continue to be high. Moving back to a discussion of the technology I think something to watch (admittedly over the next decade or so....) is the risk of chromothripsis discussed in this article Crispr: Bad News For Gene Editing The associated disussion is also worth wading through, although rather like this forum includes nuggets but also a few too many brickbats. IMHO, even if there proves to be an issue there may be an argument for proceding with treatment for patients with chronic disease, against an apparently modest (but non trivial) risk of developing another serious illness many years down the line. MXCT also potentially benefits from the diversity of its partnerships. Restriction enzymes like those deployed by partner Precision Biosciences may be less vulnerable to chromothripsis complications than Crispr Cas9. It would also be reassuring if Beam Therapeutics ever progresses to a MXCT SPL (we know it uses electroporation in its pre clinical work in hematology and oncology) as Beam's base editing technology does not require a double helix break.

[trident5] 29/9/2021 10:43

Agreed. But there were peeps on here who have been constantly stating that an American listing would drive the price up. It hasn't.

Elsewhere on these boards this argument is frequently made but never seems to deliver, and investors should be wary of it.

Of course, we don't know the counterfactual - if it hadn't listed the price could be even lower, but we do know that our slices of the pie would not have reduced.

[nimbo1] 29/9/2021 10:40

At this point its a fair comment - I hoped the price would double after US IPO...however the price did very well before had and clearly a lot has been priced in already. I would point out this is following a similar path timing wise to renx...and that did indeed double after a period of weakness post US IPO. So who knows what will happen.

I've now seen about 6 tweets Maxcyte have posted of themselves ringing the closing bell on nasdaq looking a bit too pleased with themselves for my liking! 1 is fine of course...

[mysteronz] 29/9/2021 08:50

If you care about a 3 month timeline, most serious investors will be here for 3+ Years